NICE issues positive recommendation on use of new epilepsy drug in the UK
A new epilepsy medication developed for the treatment of focal-onset seizures in adults has moved a step closer to being reimbursed in the UK.
ONTOZRY® (also known as Cenobamate) has previously posted positive results regarding its efficacy in the treatment of these seizures through clinical trials with 40-64% of patients (depending on dose) experiencing a 50% drop in the frequency of their seizures during 3 months of treatment compared with 26% of patients taking placebo.